NeOAdjuvant Herceptin (NOAH) trial: formalin-fixed, paraffin-embedded breast cancer biopsies
Summary:
Analysis of FFPE core biopsies from pre-treated patients with HER2+ breast cancer (BC) randomized to receive neoadjuvant chemotherapy only or chemotherapy+trastuzumab (herceptin). Results provide insight into the molecular basis of survival outcomes following trastuzumab-based chemotherapy.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Prat A, Bianchini G, Thomas M, Belousov A et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 2014 Jan 15;20(2):511-21. PMID: 24443618
